HALO.NASDAQHalozyme Therapeutics, INC
Form 4: Halozyme Therapeutics CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Helen Torley, PRESIDENT AND CEO and a Director of Halozyme Therapeutics, Inc., sold 60,000 shares of common stock on August 17, 2026.
Summary
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on August 17, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 900 Common Stock at $98.96 ($89,062) on August 17, 2026; holds 786,880 after (Direct).
- Open-market sale: disposed of 500 Common Stock at $100.46 ($50,228) on August 17, 2026; holds 786,380 after (Direct).
- Open-market sale: disposed of 2,100 Common Stock at $101.77 ($213,709) on August 17, 2026; holds 784,280 after (Direct).
- Open-market sale: disposed of 9,000 Common Stock at $102.55 ($922,977) on August 17, 2026; holds 775,280 after (Direct).
- Open-market sale: disposed of 7,500 Common Stock at $103.48 ($776,115) on August 17, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on August 18, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 5,703 Common Stock at $103.08 ($587,882) on August 18, 2026; holds 782,077 after (Direct).
- Open-market sale: disposed of 4,897 Common Stock at $104.11 ($509,827) on August 18, 2026; holds 777,180 after (Direct).
- Open-market sale: disposed of 9,400 Common Stock at $104.87 ($985,816) on August 18, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on August 19, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 7,200 Common Stock at $106.36 ($765,778) on August 19, 2026; holds 780,580 after (Direct).
- Open-market sale: disposed of 9,600 Common Stock at $107.22 ($1,029,350) on August 19, 2026; holds 770,980 after (Direct).
- Open-market sale: disposed of 3,200 Common Stock at $107.77 ($344,848) on August 19, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on August 17, 2026; holds 181,552 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on August 18, 2026; holds 161,552 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on August 19, 2026; holds 141,552 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,275,592 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Helen Torley — Director, Officer (PRESIDENT AND CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-08-17 | Open-market sale | Common Stock | 900 | $99 | $89.1K | 786,880 |
| 2026-08-17 | Open-market sale | Common Stock | 500 | $100 | $50.2K | 786,380 |
| 2026-08-17 | Open-market sale | Common Stock | 2,100 | $102 | $213.7K | 784,280 |
| 2026-08-17 | Open-market sale | Common Stock | 9,000 | $103 | $923.0K | 775,280 |
| 2026-08-17 | Open-market sale | Common Stock | 7,500 | $103 | $776.1K | 767,780 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-08-18 | Open-market sale | Common Stock | 5,703 | $103 | $587.9K | 782,077 |
| 2026-08-18 | Open-market sale | Common Stock | 4,897 | $104 | $509.8K | 777,180 |
| 2026-08-18 | Open-market sale | Common Stock | 9,400 | $105 | $985.8K | 767,780 |
| 2026-08-19 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-08-19 | Open-market sale | Common Stock | 7,200 | $106 | $765.8K | 780,580 |
| 2026-08-19 | Open-market sale | Common Stock | 9,600 | $107 | $1.0M | 770,980 |
| 2026-08-19 | Open-market sale | Common Stock | 3,200 | $108 | $344.8K | 767,780 |
| 2026-08-17 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 181,552 |
| 2026-08-18 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 161,552 |
| 2026-08-19 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 141,552 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Option exercise/conversion (20,000 shares) |
| 2026-08-17 | Open-market sale (900 shares) |
| 2026-08-17 | Open-market sale (500 shares) |
| 2026-08-17 | Open-market sale (2,100 shares) |
| 2026-08-17 | Open-market sale (9,000 shares) |
| 2026-08-17 | Open-market sale (7,500 shares) |
| 2026-08-18 | Option exercise/conversion (20,000 shares) |
| 2026-08-18 | Open-market sale (5,703 shares) |
| 2026-08-18 | Open-market sale (4,897 shares) |
| 2026-08-18 | Open-market sale (9,400 shares) |
| 2026-08-19 | Option exercise/conversion (20,000 shares) |
| 2026-08-19 | Open-market sale (7,200 shares) |
| 2026-08-19 | Open-market sale (9,600 shares) |
| 2026-08-19 | Open-market sale (3,200 shares) |
| 2026-08-17 | Option exercise/conversion (20,000 shares) |
| 2026-08-18 | Option exercise/conversion (20,000 shares) |
| 2026-08-19 | Option exercise/conversion (20,000 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., bearish, Helen Torley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.